Source:http://linkedlifedata.com/resource/pubmed/id/12180114
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0003442,
umls-concept:C0013018,
umls-concept:C0018133,
umls-concept:C0023470,
umls-concept:C0030705,
umls-concept:C0035020,
umls-concept:C0035647,
umls-concept:C0039194,
umls-concept:C0205170,
umls-concept:C0333668,
umls-concept:C0392756,
umls-concept:C0439849,
umls-concept:C0445223,
umls-concept:C1504389,
umls-concept:C1515655,
umls-concept:C1527169,
umls-concept:C1552599,
umls-concept:C1704787,
umls-concept:C1708943
|
| pubmed:issue |
8
|
| pubmed:dateCreated |
2002-8-15
|
| pubmed:abstractText |
One-hundred and two patients with good risk myeloid leukemia (CML first chronic phase or AML first CR) were transplanted from HLA-related donors after conditioning with (n = 45) or without anti-thymocyte globulin (ATG) (n = 57). One graft failure was observed in the non-ATG and none in the ATG group. The median time to leukocyte engraftment (> 1 x 10(9)/l) was 16 (range 12-33) in the ATG group and 17 days (range 11-29) in the non-ATG group (NS) and for platelet engraftment (> 20 x 10(9)/l) 24 and 19 days (P = 0.002), respectively. Acute GVHD grade II-IV was observed in 47% of the non-ATG and in 20% of the ATG group (P = 0.004). Grade III/IV GVHD occurred in 7% of the ATG and in 32% of the non-ATG group (P = 0.002). Chronic GVHD was seen in 36% and 67% (P = 0.005), respectively. After a median follow-up of 48 months (range 2-128), the 5-year estimated OS is 66% (95% KI: 51-81%) for the ATG group and 59% (95% KI: 46-72%) for the non-ATG group (NS). The 5-year estimated DFS is 64% (95% KI: 50-78%) for ATG and 55% (95% KI: 43-67%) for the non-ATG regimen (NS). The 5-year probability of relapse was 5% in the ATG and 15% in the non-ATG group (NS). ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AyubMM,
pubmed-author:ErttmannRR,
pubmed-author:FiegelHH,
pubmed-author:KrögerNN,
pubmed-author:KrügerWW,
pubmed-author:LöligerCC,
pubmed-author:RengeiBB,
pubmed-author:RischewskiJJ,
pubmed-author:SchadeUU,
pubmed-author:SonnenbergSS,
pubmed-author:StuteNN,
pubmed-author:TögelFF,
pubmed-author:ZabelinaTT,
pubmed-author:ZanderA RAR
|
| pubmed:issnType |
Print
|
| pubmed:volume |
29
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
683-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12180114-Adolescent,
pubmed-meshheading:12180114-Adult,
pubmed-meshheading:12180114-Antilymphocyte Serum,
pubmed-meshheading:12180114-Child,
pubmed-meshheading:12180114-Disease-Free Survival,
pubmed-meshheading:12180114-Female,
pubmed-meshheading:12180114-Graft vs Host Disease,
pubmed-meshheading:12180114-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12180114-Humans,
pubmed-meshheading:12180114-Leukemia, Myeloid, Acute,
pubmed-meshheading:12180114-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:12180114-Lymphocyte Depletion,
pubmed-meshheading:12180114-Male,
pubmed-meshheading:12180114-Middle Aged,
pubmed-meshheading:12180114-T-Lymphocytes,
pubmed-meshheading:12180114-Tissue Donors,
pubmed-meshheading:12180114-Transplantation, Homologous
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
|
| pubmed:affiliation |
Bone Marrow Transplantation, University Hospital, Hamburg-Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany.
|
| pubmed:publicationType |
Journal Article
|